Avalo Net Income From Continuing Ops from 2010 to 2026
| AVTX Stock | USD 14.35 0.26 1.78% |
Net Loss | First Reported 2020-06-30 | Previous Quarter -20.8 M | Current Value -30.6 M | Quarterly Volatility 36 M |
Check Avalo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avalo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 184.6 K, Selling General Administrative of 11.8 M or Total Revenue of 377.1 K, as well as many indicators such as Price To Sales Ratio of 150, Dividend Yield of 0.0 or PTB Ratio of 0.43. Avalo financial statements analysis is a perfect complement when working with Avalo Therapeutics Valuation or Volatility modules.
Avalo | Net Income From Continuing Ops | Build AI portfolio with Avalo Stock |
The evolution of Net Income From Continuing Ops for Avalo Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Avalo Therapeutics compares to historical norms and industry peers.
Latest Avalo Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Avalo Therapeutics over the last few years. It is Avalo Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avalo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Avalo Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (16,757,946) | |
| Coefficient Of Variation | (186.65) | |
| Mean Deviation | 27,001,100 | |
| Median | (16,270,753) | |
| Standard Deviation | 31,279,433 | |
| Sample Variance | 978.4T | |
| Range | 96.2M | |
| R-Value | (0.73) | |
| Mean Square Error | 481T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (4,548,116) | |
| Total Sum of Squares | 15654.4T |
Avalo Net Income From Continuing Ops History
About Avalo Therapeutics Financial Statements
Avalo Therapeutics investors use historical fundamental indicators, such as Avalo Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Avalo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -31.6 M | -33.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.